Impact of the Preprocedural Frequency of Paroxysmal Atrial Fibrillation on the Clinical Outcome after Catheter Ablation

Background: Pulmonary vein antral isolation (PVAI) is a recommended treatment for symptomatic drug‐refractory paroxysmal atrial fibrillation (PAF). PAF naturally progresses toward persistent AF with an increase in the frequency and duration of AF. The objective of this study was to evaluate whether the preprocedural AF frequency had an impact on the AF recurrence after PVAI in patients with symptomatic PAF. Methods and Results: A total of 362 consecutive patients (61.0 ± 9.8 years; 274 males) with drug‐refractory PAF who underwent PVAI were included. The preprocedural frequency of PAF was daily, weekly, monthly, and yearly in 145 (40.1%), 112 (30.9%), 90 (24.9%), and 15 (4.1%) patients, respectively. There were no significant differences in any of the preprocedural variables between the four groups, except for the number of ineffective antiarrhythmic drugs (AADs). PVAI was successfully performed in all patients. At 12 months after the initial procedure, 63.5% of the entire group of patients were free of AF recurrences without any AADs, respectively. A Cox regression multivariate analysis of the variables including the AF frequency, age, gender, duration of AF, presence of hypertension or structural heart disease, left atrial size, left ventricular ejection fraction, and body mass index demonstrated that the AF frequency was not an independent predictor of AF recurrence after a single ablation procedure (P = 0.194). Conclusions: This study demonstrated that the preprocedural AF frequency did not predict AF recurrence after PVAI in patients with PAF. From the clinical point of view, an additional AF classification based on the preprocedural AF frequency might not be valuable in patients undergoing PVAI. (PACE 2012; 35:1236–1241)     

Cost Analysis of Catheter Ablation for Paroxysmal Atrial Fibrillation

WEERASOORIYA, R., et al. : Cost Analysis of Catheter Ablation for Paroxysmal Atrial Fibrillation . RF ablation for paroxysmal atrial fibrillation (PAF) is a curative treatment, which when successful, eliminates the need to take antiarrhythmic drugs, be anticoagulated, and have recurrent physician visits or hospital admissions. The authors performed a retrospective cost comparison of RF ablation versus drug therapy for PAF. The study population consisted of 118 consecutive patients with symptomatic, drug refractory PAF who underwent   1.52 ± 0.71   RF ablation procedures (range 1–4) for PAF. During a follow-up of 32 ± 15 weeks, 85 (72%) patients remained free of clinical recurrence in absence of antiarrhythmic drugs. The cost of RF ablation was calculated in the year 2001 euros on the basis of resource use. The mean cost of pharmacologic treatment prior to ablation was 1,590 euros/patient per year. The initial cost of RF ablation for PAF was 4,715 euros, then 445 euros/year. After 5 years, the cost of RF ablation was below that of ongoing medical management, and continued to diverge thereafter. RF catheter ablation may be a cost-effective alternative to long-term drug therapy in patients with symptomatic, drug refractory PAF. (PACE 2003; 26[Pt. II]:292–294)     

Catheter Ablation for Paroxysmal Atrial Fibrillation: A Randomized Comparison between Multielectrode Catheter and Point‐by‐Point Ablation

Introduction: Catheter ablation for paroxysmal atrial fibrillation is widely used for patients with drug‐refractory paroxysms of arrhythmia. Recently, novel technologies have been introduced to the market that aim to simplify and shorten the procedure. Aim: To compare the clinical outcome of pulmonary vein (PV) isolation using a multipolar circular ablation catheter (PVAC group), with point‐by‐point PV isolation using an irrigated‐tip ablation catheter and the CARTO mapping system (CARTO group; CARTO, Biosense Webster, Diamond Bar, CA, USA). Methods: Patients with documented PAF were randomized to undergo PV isolation using PVAC or CARTO. Atrial fibrillation (AF) recurrences were documented by serial 7‐day Holter monitoring. Results: One hundred and two patients (mean age 58 ± 11 years, 68 men) were included in the study. The patients had comparable baseline clinical characteristics, including left atrial dimensions and left ventricular ejection fraction, in both study arms (PVAC: n = 51 and CARTO: n = 51). Total procedural and fluoroscopic times were significantly shorter in the PVAC group (107 ± 31 minutes vs 208 ± 46 minutes, P < 0.0001 and 16 ± 5 minutes vs 28 ± 8 minutes, P < 0.0001, respectively). The AF recurrence was documented in 23% and 29% of patients in the PVAC and CARTO groups, respectively (P = 0.8), during the mean follow‐up of 200 ± 13 days. No serious complications were noted in both study groups. Conclusions: Clinical success rates of PV isolation are similar when using multipolar circular PV ablation catheter and point‐by‐point ablation with a three‐dimensional (3D) navigation system in patients with PAF, and results in shorter procedural and fluoroscopic times with a comparable safety profile. (PACE 2010; 33:1039–1046)     

Role of Pulmonary Veins Isolation in Persistent Atrial Fibrillation Ablation:

Background: The role of pulmonary veins (PV) isolation in patients with persistent atrial fibrillation (AF) is still debated. The aim of this study was to evaluate the adjunctive role of PV isolation in patients with persistent AF who underwent circumferential PV ablation (anatomical approach).
Methods: We treated 97 consecutive patients presenting with drug-refractory persistent AF by an anatomical approach (group A, n = 36, mean age = 60 ± 8 years, 29 males) or an integrated approach (group B, n = 61, mean age 59 ± 10 years, 48 males). In all patients, radiofrequency (RF) ablation was performed by means of a nonfluoroscopic navigation system, in order to anatomically create circumferential lines around the PV. In group B, the persistence of PV potentials was ascertained with a multipolar circular catheter. If PV potentials persisted, RF energy targeting the electrophysiological breakthroughs was delivered to disconnect the PV. Past a 2-month period of observation, success was defined as absence of any atrial tachyarrhythmia recurrence lasting >30 seconds.
Results: Total procedure duration (220 ± 62 minutes vs 140 ± 43 minutes, P < 0.001), fluoroscopy time (35 ± 15 minutes vs 17 ± 9 minutes, P < 0.001), and RF delivery time (48 ± 22 minutes vs 27 ± 9 minutes, P < 0.001) were significantly longer in group B than in group A. One cardiac perforation occurred in group A. After 15 ± 9.1 months, 21 patients in group A (58%) and 34 patients in group B (56%) were free of atrial tachyarrhythmia recurrence (P = 0.9).
Conclusions: In patients with persistent AF, who underwent an anatomical approach, electrophysiological confirmation of PV disconnection significantly increased the fluoroscopy and procedural times, without effect on the long-term outcomes.     

Transvenous Catheter Cryoablation for Treatment of Atrial Fibrillation:

Pulmonary vein (PV) isolation using radiofrequency (RF) ablation can induce PV stenosis. Cryoablation may offer a safer alternative energy source for PV isolation. PV isolation with cryoablation was attempted in 31 patients with paroxysmal atrial fibrillation (AF). Event monitors were used to measure the AF episode burden. Serial spiral CT scans were obtained to monitor PV stenosis pre- and postcryoablation. Cryoablation was immediately successful for PV isolation in 29 of 31 patients (94%), with 5.9 ± 1.2 months of follow-up. Additional RF ablation was performed for AF recurrences in seven patients. The remaining 22 patients with a single cryoablation procedure demonstrated a time-dependent, long-term reduction in the frequency of AF episodes. At 6 months of follow-up, 18 of 22 of cryo-treated only patients (82%) were free of symptomatic AF episodes, and antiarrhythmic drugs were discontinued in 12 of 22 patients. Serial spiral CT scans demonstrated no change in the cryo-treated PV ostial diameter. PV cryoablation was effective to control paroxysmal AF in most patients. Early recurrences of AF postcryoablation were common, though tended to resolve within 6 months postablation, consistent with a process of reverse atrial remodeling. Cryoablation of the PVs did not cause PV stenosis or other serious adverse events.     

Catheter Ablation of Chronic Atrial Fibrillation with Noncontact Mapping:

SEIDL, K., et al .: Catheter Ablation of Chronic Atrial Fibrillation with Noncontact Mapping: Are Continuous Linear Lesions Associated with Ablation Success? Catheter-based, right and left atrial compartmentalization procedure was evaluated using a noncontact mapping (NCM) system. Its usefulness to identify and close discontinuities in linear lesions in both atria was evaluated. The impact of linear lesion continuity on ablation success of chronic AF was also investigated. Nineteen patients with symptomatic, drug refractory chronic AF were studied. Right atrial ablation with three predefined lines was attempted in all patients. In 18 patients, left atrial ablation was performed with four linear lesions. During a follow-up of 12 ± 3 months , 6 of 19 patients remained in sinus rhythm (SR) without antiarrhythmic agents (AAs). In addition, four patients were maintained in SR with AA. Thirteen of 14 patients with gaps identified during off-line analysis had recurrence of AF. Only one patient with a gap was free of recurrence without AAs. In the remaining five patients without recurrence of AF, no gap was observed during off-line analysis. In all four patients who were free of AF with additional treatment of AAs, two gaps had been identified. In the remaining nine patients with chronic AF recurrence, a mean of 4.9 gaps were identified. Excluding the initial learning period (first five patients) the success rate increased to 43% (6/14 patients) without and to 71% (10/14 patients) with AA. NCM identifies discontinuities in lines of ablation. Successful ablation of chronic AF is associated with continuity of linear lesions and good clinical technique demands a vigilant search for and closure of every gap. (PACE 2003; 26[Pt. I]:534–543)     

Catheter Ablation for Atrial Fibrillation

Atrial fibrillation (AF) is the most common arrhythmia in adults, and its prevalence is on the rise. Catheter ablation of AF, once considered a novel procedure, has become the most commonly performed technique for treating patients with severe symptomatic AF. This article reviews the latest American Heart Association/American College of Cardiology/Heart Rhythm Society guideline on the indications for AF and summarizes techniques available to achieve freedom of recurrent arrhythmia and relief from symptoms. Nurse practitioners need to provide guideline-directed care before, during, and after catheter ablation to improve patients’ quality of life and prevent complications.     

Contemporary Challenges of Catheter Ablation for Atrial Fibrillation

Purpose

Catheter ablation of atrial fibrillation (AF) is now one of the most frequently performed ablation procedures, but there are currently 2 important challenges: achieving permanent/durable rather than transient pulmonary vein isolation (PVI) and improving the results of ablation for the wider patient population with persistent AF.

Methods

Recent technical advances in the technique of ablation and the results of clinical trials aimed at achieving more permanent and durable PVI are reviewed. We also summarize recent advances in identifying atrial fibrosis and in understanding the pathophysiology of AF relevant to selecting patients for ablation of persistent AF.

Findings

The use of contact force–sensing technology, adenosine testing after ablation, and pace capture–guided ablation all have the potential for achieving more durable ablation. Selection of patients suitable for ablation of persistent AF may be improved by assessing the extent of atrial fibrosis with delayed enhancement imaging with cardiac magnetic resonance or by assessing the pattern of atrial electrical activity with the use of complex atrial electrograms. Advances in treatment are likely to result from the recognition of localized rotors and focal sources as primary sustaining mechanisms for all types of human AF and in the use of noninvasive mapping for their identification. Linear ablation to supplement PVI may improve the results of AF ablation.

Implications

Rapidly unfolding advances in the techniques of AF ablation and the understanding of mechanisms of AF hold promise for improving the durability of PVI and for extending the technique to carefully selected patients with persistent AF.     

Anatomy-Guided Linear Atrial Lesions for Radiofrequency Catheter Ablation of Atrial Fibrillation

The surgical atrial maze procedure has provided proof that atrial fibrillation can be cured by performing atrial incisions based on anatomical and electrophysiological principles. Preliminary reports of attempts at radio frequency catheter ablation of atrial fibrillation utilizing an anatomy-based "linear incision" method have shown the feasibility of the method. However, postprocedural atrial fibrillation recurrence has been common and in addition new, uniform tachycardias have developed in some patients. Both of these outcomes may be in part due to incomplete or inconsistent lesion deployment. This article details the use of the CARTO system for deploying anatomy guided linear atrial lesions for the purpose of curing atrial fibrillation. The procedure is comprised of three phases, which are discussed in detail: (1) baseline map: (2) lesion deployment and; (3) lesion assessment. Using a single standard ablation electrode, lesions can be deployed safely, and complete lesions can be confirmed. Paradigms for right and left atrial incisions are proposed.     

经导管射频消融治疗阵发性心房颤动临床研究

[目的]探讨经导管射频消融治疗阵发性心房颤动的有效性与安全性.[方法]60例阵发性心房颤动患者药物治疗无效且反复发作,采用节段性消融肺静脉电隔离术、CARTO和EnSite 3000三维空间标测系统指导下肺静脉电隔离术3种不同的方法进行肺静脉电位经导管射频消融隔离治疗,术后随访3～41个月.[结果]60例患者中42例(70.0%)经消融成功,10例(16.7%)有效,8例(13.3%)失败,无严重并发症;CARTO和EnSite 3000三维空间标测系统指导肺静脉电隔离术可明显减少X线曝光时间.[结论]经导管射频消融治疗局灶性心房颤动是可行的,对大部分患者是有效的.     

Acute and Chronic Pulmonary Vein Reconnection after Atrial Fibrillation Ablation: A Prospective Characterization of Anatomical Sites

Background: Arrhythmia recurrence after atrial fibrillation (AF) ablation is often associated with pulmonary vein reconnection (PVR). We prospectively examined anatomical sites of both acute and chronic PVR. Methods: One hundred and fifty AF patients underwent PV wide encirclement and sites where immediate electrical isolation (EI) occurred were tagged using electroanatomic mapping/CT integration (Cartomerge?, Biosense Webster, Diamond Bar, CA, USA). After 30 minutes PVs were checked and acute PVR sites marked at reisolation. Chronic PVR sites were marked at the time of repeat procedures. Results: On the left, immediate EI sites were predominantly on the intervenous ridge (IVR) and PV‐left atrial appendage (PV‐LAA) ridge. On the right they were at the roof, IVR, and floor of the PVs. Ninety‐eight of one hundred and fifty patients had PVs checked after >30 minutes. Thirty‐two of ninety‐eight had acute PVR. This was mostly on the IVR and PV‐LAA ridge on the left (88%), and on the roof and IVR on the right (78%). At repeat procedure, 38/39 patients had chronic PVR, predominantly on the IVR (61%) and PV‐LAA ridge (21%) on the left, and on the roof, IVR, and floor of the right PVs (79%). There was minimal acute or chronic PVR posteriorly. Acutely PVR occurred close to the immediate EI site 60% of the time, but only 30% of the time chronically. Conclusion: Acute and chronic PVR sites have a preferential distribution. This may be determined by anatomical and technical factors. Knowledge of immediate EI sites may be beneficial acutely, but with chronic PVR a careful survey is required. These findings may help target ablation, improving safety and success.     

Linear Ablation Following Pulmonary Vein Isolation in Patients with Atrial Fibrillation: A Meta‐Analysis

Previous studies have given conflicting data regarding the long‐term adjunctive efficacy of linear lesions (LLs) on top of pulmonary vein isolation (PVI) as an ablation strategy in patients with atrial fibrillation (AF). The aim of this meta‐analysis was to provide a detailed analysis of the available randomized controlled trials (RCTs) regarding the efficacy of LL following PVI in AF patients. Current databases were searched until October 2015. The primary outcome end point of the meta‐analysis was recurrence of any symptomatic or documented episode of AF or atrial tachycardia after a single ablation procedure with or without the use of antiarrhythmic drugs. Ten RCTs with a total of 1,446 patients were included in the meta‐analysis. The pooled analysis of five trials concerning persistent AF (PeAF) patients (400 in PVI plus LL group and 182 in PVI alone group) suggested that the addition of LL following PVI does not lead to a significant reduction in recurrent atrial tachyarrhythmias compared with PVI alone (relative ratio [RR] = 0.73, 95% confidence interval [CI]: 0.44–1.21, P = 0.22). Similarly, there was no incremental benefit of additional LL in long‐term outcomes in paroxysmal AF (PAF) patients (RR = 0.85, 95% CI: 0.68–1.05, P = 0.13). Pooling the results of all eligible trials suggested that PVI plus LL compared with PVI alone significantly increased radiofrequency time (P = 0.0002), fluoroscopy time (P < 0.00001), and procedure time (P < 0.0001). This meta‐analysis suggests that LL following PVI does not provide additional benefit to sinus rhythm maintenance in patients with PeAF and PAF.     

Radiation Exposure During Radiofrequency Catheter Ablation for Atrial Fibrillation

MACLE, L., et al. : Radiation Exposure During Radiofrequency Catheter Ablation for Atrial Fibrillation. RF catheter ablation of paroxysmal atrial fibrillation (PAF) is associated with prolonged fluoroscopy. The procedural duration and fluoroscopic exposure to patients and medical staff were recorded and compared among 43 ablation procedures for PAF, 20 for common atrial flutter, and 16 for accessory pathways. Patient radiation exposure was measured by dosimeters placed over the xyphoid, while that of physicians and nurses was measured by dosimeters placed outside and inside the lead apron. The mean fluoroscopy time was   57 ± 30   minutes for PAF,   20 ± 10   minutes for common flutter, and   22 ± 21   minutes for accessory pathway ablation. The patient median radiation exposure was 1110μSv for PAF, compared with 500 μSv for common flutter and 560 μSv for accessory pathway ablation (P < 0.01). The median radiation exposure to physician and nurse inside the lead apron were, respectively, 2 μSv and 3 μSv for PAF, 1 μSv and 2 μSv for common flutter, and <0.5 μSv and 3 μSv for accessory pathway ablations. RF catheter ablation for PAF was associated with prolonged fluoroscopy times and a twofold higher radiation exposure to the patient and physician compared with other ablation procedures. Assuming 300 procedures/year, radiation exposure to the medical staff was below the upper recommended annual dose limit. (PACE 2003; 26[Pt. II]:288–291)